The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...

The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration ...

Amgen also tested MariTide in a population with Type 2 diabetes, a group that tends to lose less weight with the new obesity ...

In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs ...

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.

Medicare has been barred from offering the drugs under a decades-old law that prohibits the government-backed insurance ...

The Biden administration is proposing to expand coverage of anti-obesity medicines for those with Medicare and Medicaid.

STORY: Novo Nordisk and Eli Lilly shares rose on Tuesday ().Investors were excited as U.S. President Joe Biden proposed ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

Medicare coverage would reduce out-of-pocket costs for AOMs – which can currently be as high as $1,000 a month - by as much ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...